{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:29:47Z","timestamp":1787020187738,"version":"build-2736575974"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,4,28]],"date-time":"2022-04-28T00:00:00Z","timestamp":1651104000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,4,28]],"date-time":"2022-04-28T00:00:00Z","timestamp":1651104000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Diabetic nephropathy is the leading cause of kidney failure. Clinical practice guidelines recommend prescribing renin\u2013angiotensin aldosterone system inhibitors (RAASi) to prevent diabetic nephropathy at any stage. We conducted this systematic review and meta-analysis to compare the effects of RAASi with placebo and other antihypertensive agents in adults with diabetes on continuous and binary kidney outcomes to provide a comprehensive review of the class effect of RAASi on several subgroups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A systematic electronic search to identify randomized clinical trials of a duration of\u2009\u2265\u200912\u00a0months that recruited\u2009\u2265\u200950 adult participants with type 1 or 2 diabetes with any stage of chronic kidney disease and proteinuria was conducted in MEDLINE, CINAHL, EMBASE, and Cochrane library with no language restriction. Studies were screened against the inclusion and exclusion criteria by two reviewers independently.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      In this meta-analysis, evidence was drawn from 26,551 patients with diabetes from 46 studies. Our analysis shows that RAASi were better than placebo in reducing SrCr (the raw mean difference [RMD]\u2009=\u2009-13.4 \u03bcmol\/L; 95%CI: -16.78; -10.01) and albuminuria levels (standardized mean difference [SMD]\u2009=\u2009-1; 95%CI: -1.57, -0.44, I\n                      <jats:sup>2<\/jats:sup>\n                      \u2009=\u200996%). When compared to other active treatments, RAASi did not reduce SrCr (RMD\u2009=\u20090.03 \u03bcmol\/L; 95%CI: -6.4, 6.10, I\n                      <jats:sup>2<\/jats:sup>\n                      \u2009=\u200976%), caused a non-significant reduction of GFR levels (RMD\u2009=\u2009-1.21\u00a0mL\/min; 95%CI: -4.52, 2.09, I\n                      <jats:sup>2<\/jats:sup>\n                      \u2009=\u200986%), and resulted in modest reduction of albuminuria levels (SMD\u2009=\u2009-0.55; 95%CI: -0.95, -0.16, I\n                      <jats:sup>2<\/jats:sup>\n                      \u2009=\u200990%). RAASi were superior to placebo in reducing the risks of kidney failure (OR\u2009=\u20090.74; 95%CI: 0.56, 0.97) and doubling of serum creatinine levels (SrCr; OR\u2009=\u20090.71; 95%CI: 0.55, 0.91), but not in promoting the regression of albuminuria (OR\u2009=\u20093.00; 95%CI: 0.96, 9.37). RAASi, however, were not superior to other antihypertensives in reducing the risks of these outcomes. Patients with type 2 diabetes, macroalbuminuria and longer duration of diabetes had less risk of developing kidney failure in placebo-controlled trials, while longer duration of diabetes, normal kidney function, and hypertension increased the probability of achieving regression of albuminuria in active-controlled trials.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>While our findings revealed the non-superiority of RAASi over other antihypertensives and portrayed a class effect on several subgroups of study participants, it raised a challenging question on whether RAASi deserve their place as first-line therapy in managing diabetic nephropathy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12882-022-02763-1","type":"journal-article","created":{"date-parts":[[2022,4,28]],"date-time":"2022-04-28T09:08:12Z","timestamp":1651136892000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["The effect of renin\u2013angiotensin\u2013aldosterone system inhibitors on continuous and binary kidney outcomes in subgroups of patients with diabetes: a meta-analysis of randomized clinical trials"],"prefix":"10.1186","volume":"23","author":[{"given":"Noor","family":"Alsalemi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheryl A.","family":"Sadowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoual","family":"Elftouh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maudeline","family":"Louis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelley","family":"Kilpatrick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherilyn K. D.","family":"Houle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Philippe","family":"Lafrance","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,4,28]]},"reference":[{"issue":"2","key":"2763_CR1","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1053\/j.ackd.2017.10.011","volume":"25","author":"DN Koye","year":"2018","unstructured":"Koye DN, Magliano DJ, Nelson RG, Pavkov ME. The global epidemiology of diabetes and kidney disease. Adv Chronic Kidney Dis. 2018;25(2):121\u201332.","journal-title":"Adv Chronic Kidney Dis"},{"issue":"Suppl 1","key":"2763_CR2","doi-asserted-by":"publisher","first-page":"S135","DOI":"10.2337\/dc20-S011","volume":"43","author":"American Diabetes Association","year":"2020","unstructured":"American Diabetes Association. 11. Microvascular Complications and Foot Care: Standards of Medical Care in Diabetes\u2212 2020. Diabetes Care. 2020;43(Suppl 1):S135\u201351.","journal-title":"Diabetes Care"},{"key":"2763_CR3","doi-asserted-by":"publisher","first-page":"S88","DOI":"10.1016\/j.jcjd.2017.10.034","volume":"42","author":"L Lipscombe","year":"2018","unstructured":"Lipscombe L, Booth G, Butalia S, Dasgupta K, Eurich DT, Goldenberg R, et al. Pharmacologic glycemic management of type 2 diabetes in adults. Can J Diabetes. 2018;42:S88\u2013103.","journal-title":"Can J Diabetes"},{"issue":"4","key":"2763_CR4","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1111\/j.2040-1124.2011.00131.x","volume":"2","author":"Z Cao","year":"2011","unstructured":"Cao Z, Cooper ME. Pathogenesis of diabetic nephropathy. J Diabetes Investig. 2011;2(4):243\u20137.","journal-title":"J Diabetes Investig"},{"issue":"12","key":"2763_CR5","doi-asserted-by":"publisher","first-page":"1900","DOI":"10.1093\/ndt\/15.12.1900","volume":"15","author":"P Ruggenenti","year":"2000","unstructured":"Ruggenenti P, Remuzzi G. Nephropathy of type 1 and type 2 diabetes: diverse pathophysiology, same treatment? Nephrol Dial Transplant. 2000;15(12):1900\u20132.","journal-title":"Nephrol Dial Transplant"},{"issue":"8","key":"2763_CR6","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1016\/j.jfma.2018.02.007","volume":"117","author":"Y-C Lin","year":"2018","unstructured":"Lin Y-C, Chang Y-H, Yang S-Y, Wu K-D, Chu T-S. Update of pathophysiology and management of diabetic kidney disease. J Formos Med Assoc. 2018;117(8):662\u201375.","journal-title":"J Formos Med Assoc"},{"key":"2763_CR7","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1002\/cphy.c130040","volume":"4","author":"M Sparks","year":"2014","unstructured":"Sparks M, Crowley S, Gurley S, Mirotsou M, Coffman T. Classical renin-angiotensin system in kidney physiology. Compr Physiol. 2014;4:1201\u201328.","journal-title":"Compr Physiol"},{"issue":"3","key":"2763_CR8","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s11906-018-0823-9","volume":"20","author":"E Szczepanska-Sadowska","year":"2018","unstructured":"Szczepanska-Sadowska E, Czarzasta K, Cudnoch-Jedrzejewska A. Dysregulation of the renin-angiotensin system and the vasopressinergic system interactions in cardiovascular disorders. Curr Hypertens Rep. 2018;20(3):19.","journal-title":"Curr Hypertens Rep"},{"issue":"3","key":"2763_CR9","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1159\/000489913","volume":"43","author":"K Wang","year":"2018","unstructured":"Wang K, Hu J, Luo T, Wang Y, Yang S, Qing H, et al. Effects of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on all-cause mortality and renal outcomes in patients with diabetes and albuminuria: a systematic review and meta-analysis. Kidney Blood Press Res. 2018;43(3):768\u201379.","journal-title":"Kidney Blood Press Res"},{"issue":"3","key":"2763_CR10","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1007\/s00125-011-2398-8","volume":"55","author":"P Vejakama","year":"2012","unstructured":"Vejakama P, Thakkinstian A, Lertrattananon D, Ingsathit A, Ngarmukos C, Attia J. Reno-protective effects of renin\u2013angiotensin system blockade in type 2 diabetic patients: a systematic review and network meta-analysis. Diabetologia. 2012;55(3):566\u201378.","journal-title":"Diabetologia"},{"issue":"3","key":"2763_CR11","doi-asserted-by":"publisher","first-page":"e1001971","DOI":"10.1371\/journal.pmed.1001971","volume":"13","author":"F Catala-Lopez","year":"2016","unstructured":"Catala-Lopez F, Macias Saint-Gerons D, Gonzalez-Bermejo D, Rosano GM, Davis BR, Ridao M, et al. Cardiovascular and renal outcomes of renin\u2013angiotensin system blockade in adult patients with diabetes mellitus: a systematic review with network meta-analyses. PLoS Med. 2016;13(3):e1001971.","journal-title":"PLoS Med"},{"issue":"9502","key":"2763_CR12","doi-asserted-by":"publisher","first-page":"2026","DOI":"10.1016\/S0140-6736(05)67814-2","volume":"366","author":"JP Casas","year":"2005","unstructured":"Casas JP, Chua W, Loukogeorgakis S, Vallance P, Smeeth L, Hingorani AD, et al. Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis. The Lancet. 2005;366(9502):2026\u201333.","journal-title":"The Lancet"},{"issue":"7","key":"2763_CR13","doi-asserted-by":"publisher","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","volume":"6","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097.","journal-title":"PLoS Med"},{"key":"2763_CR14","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1136\/bmj.n71","volume":"321","author":"M Page","year":"2021","unstructured":"Page M, McKenzie J, Bossuyt P, Boutron I, Hoffmann T, Mulrow C. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;321:71.","journal-title":"BMJ"},{"issue":"7","key":"2763_CR15","doi-asserted-by":"publisher","first-page":"e0180355","DOI":"10.1371\/journal.pone.0180355","volume":"12","author":"F Catal\u00e1-L\u00f3pez","year":"2017","unstructured":"Catal\u00e1-L\u00f3pez F, Hutton B, N\u00fa\u00f1ez-Beltr\u00e1n A, Page MJ, Ridao M, Mac\u00edas Saint-Gerons D, et al. The pharmacological and non-pharmacological treatment of attention deficit hyperactivity disorder in children and adolescents: a systematic review with network meta-analyses of randomised trials. PloS One. 2017;12(7):e0180355.","journal-title":"PloS One"},{"key":"2763_CR16","unstructured":"Covidence systematic review software Melbourne, Australia: Veritas Health Innovation; [Available from: www.covidence.org."},{"key":"2763_CR17","unstructured":"Rohatgi A. WebPlotDigitizer. 4.3 ed. Pacifica, California, USA. 2020."},{"issue":"1","key":"2763_CR18","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/1471-2288-5-13","volume":"5","author":"SP Hozo","year":"2005","unstructured":"Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol. 2005;5(1):13.","journal-title":"BMC Med Res Methodol"},{"key":"2763_CR19","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","volume":"343","author":"JP Higgins","year":"2011","unstructured":"Higgins JP, Altman DG, G\u00f8tzsche PC, J\u00fcni P, Moher D, Oxman AD, et al. The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.","journal-title":"BMJ"},{"issue":"12","key":"2763_CR20","first-page":"700","volume":"33","author":"SV Faraone","year":"2008","unstructured":"Faraone SV. Interpreting estimates of treatment effects: implications for managed care. Pharmacy and Therapeutics. 2008;33(12):700.","journal-title":"Pharmacy and Therapeutics"},{"issue":"12","key":"2763_CR21","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1016\/S0011-393X(99)90003-6","volume":"60","author":"N Muirhead","year":"1999","unstructured":"Muirhead N, Feagan BF, Mahon J, Lewanczuk RZ, Rodger NW, Botteri F, et al. The effects of valsartan and captopril on reducing microalbuminuria in patients with type 2 diabetes mellitus: a placebo-controlled trial. Curr Ther Res. 1999;60(12):650\u201360.","journal-title":"Curr Ther Res"},{"issue":"12","key":"2763_CR22","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1016\/S0895-7061(02)03017-0","volume":"15","author":"R Fogari","year":"2002","unstructured":"Fogari R, Preti P, Zoppi A, Rinaldi A, Corradi L, Pasotti C, et al. Effects of amlodipine fosinopril combination on microalbuminuria in hypertensive type 2 diabetic patients. Am J Hypertens. 2002;15(12):1042\u20139.","journal-title":"Am J Hypertens"},{"issue":"19","key":"2763_CR23","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1056\/NEJMoa042167","volume":"351","author":"P Ruggenenti","year":"2004","unstructured":"Ruggenenti P, Fassi A, Ilieva AP, Bruno S, Iliev IP, Brusegan V, et al. Preventing microalbuminuria in type 2 diabetes. N Engl J Med. 2004;351(19):1941\u201351.","journal-title":"N Engl J Med"},{"issue":"2","key":"2763_CR24","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1097\/HJH.0b013e32834069bd","volume":"29","author":"P Ruggenenti","year":"2011","unstructured":"Ruggenenti P, Fassi A, Ilieva AP, Iliev IP, Chiurchiu C, Rubis N, et al. Effects of verapamil added-on trandolapril therapy in hypertensive type 2 diabetes patients with microalbuminuria: the BENEDICT-B randomized trial. J Hypertens. 2011;29(2):207\u201316.","journal-title":"J Hypertens"},{"issue":"9590","key":"2763_CR25","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/S0140-6736(07)61303-8","volume":"370","author":"ADVANCE Collaborative Group","year":"2007","unstructured":"ADVANCE Collaborative Group. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. The Lancet. 2007;370(9590):829\u201340.","journal-title":"The Lancet"},{"issue":"12","key":"2763_CR26","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.2337\/diacare.23.12.1823","volume":"23","author":"P O'Hare","year":"2000","unstructured":"O\u2019Hare P, Bilbous R, Mitchell T, O\u2019Callaghan C, Viberti G, Group A-ITtLAiNI-DSS. Low-dose ramipril reduces microalbuminuria in type 1 diabetic patients without hypertension: results of a randomized controlled trial. Diabetes Care. 2000;23(12):1823\u20139.","journal-title":"Diabetes Care"},{"issue":"5","key":"2763_CR27","doi-asserted-by":"publisher","first-page":"919","DOI":"10.2337\/diacare.24.5.919","volume":"24","author":"M Bojestig","year":"2001","unstructured":"Bojestig M, Karlberg BE, Lindstr\u00f6m T, Nystrom FH. Reduction of ACE activity is insufficient to decrease microalbuminuria in normotensive patients with type 1 diabetes. Diabetes Care. 2001;24(5):919\u201324.","journal-title":"Diabetes Care"},{"issue":"12","key":"2763_CR28","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1056\/NEJMoa011489","volume":"345","author":"H-H Parving","year":"2001","unstructured":"Parving H-H, Lehnert H, Br\u00f6chner-Mortensen J, Gomis R, Andersen S, Arner P. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med. 2001;345(12):870\u20138.","journal-title":"N Engl J Med"},{"issue":"4","key":"2763_CR29","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1291\/hypres.31.657","volume":"31","author":"H Makino","year":"2008","unstructured":"Makino H, Haneda M, Babazono T, Moriya T, Ito S, Iwamoto Y, et al. Microalbuminuria reduction with telmisartan in normotensive and hypertensive Japanese patients with type 2 diabetes: a post-hoc analysis of The Incipient to Overt: Angiotensin II Blocker, Telmisartan, Investigation on Type 2 Diabetic Nephropathy (INNOVATION) study. Hypertens Res. 2008;31(4):657\u201364.","journal-title":"Hypertens Res"},{"issue":"2","key":"2763_CR30","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/S0168-8227(01)00289-3","volume":"55","author":"S Katayama","year":"2002","unstructured":"Katayama S, Kikkawa R, Isogai S, Sasaki N, Matsuura N, Tajima N, et al. Effect of captopril or imidapril on the progression of diabetic nephropathy in Japanese with type 1 diabetes mellitus: a randomized controlled study (JAPAN-IDDM). Diabetes Res Clin Pract. 2002;55(2):113\u201321.","journal-title":"Diabetes Res Clin Pract"},{"issue":"3","key":"2763_CR31","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1038\/ki.1995.135","volume":"47","author":"M Ravid","year":"1995","unstructured":"Ravid M, Neumann L, Lishner M. Plasma lipids and the progression of nephropathy in diabetes mellitus type II: effect of ACE inhibitors. Kidney Int. 1995;47(3):907\u201310.","journal-title":"Kidney Int"},{"key":"2763_CR32","first-page":"S161","volume":"45","author":"M Ravid","year":"1994","unstructured":"Ravid M, Savin H, Jutrin I, Bental T, Lang R, Lishner M. Long-term effect of ACE inhibition on development of nephropathy in diabetes mellitus type II. Kidney Int Suppl. 1994;45:S161-4.","journal-title":"Kidney Int Suppl"},{"issue":"10","key":"2763_CR33","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1056\/NEJMoa1007994","volume":"364","author":"H Haller","year":"2011","unstructured":"Haller H, Ito S, Izzo JL Jr, Januszewicz A, Katayama S, Menne J, et al. Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. N Engl J Med. 2011;364(10):907\u201317.","journal-title":"N Engl J Med"},{"issue":"1","key":"2763_CR34","doi-asserted-by":"publisher","first-page":"104","DOI":"10.2337\/diacare.21.1.104","volume":"21","author":"G Crepaldi","year":"1998","unstructured":"Crepaldi G, Carta Q, Deferrari G, Mangili R, Navalesi R, Santeusanio F, et al. Effects of lisinopril and nifedipine on the progression to overt albuminuria in IDDM patients with incipient nephropathy and normal blood pressure. Diabetes Care. 1998;21(1):104\u201310.","journal-title":"Diabetes Care"},{"issue":"11","key":"2763_CR35","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1111\/j.1464-5491.2004.01316.x","volume":"21","author":"G Jerums","year":"2004","unstructured":"Jerums G, Allen TJ, Campbell D, Cooper ME, Gilbert RE, Hammond J, et al. Long-term renoprotection by perindopril or nifedipine in non-hypertensive patients with Type 2 diabetes and microalbuminuria. Diabet Med. 2004;21(11):1192\u20139.","journal-title":"Diabet Med"},{"issue":"1","key":"2763_CR36","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1056\/NEJMoa0808400","volume":"361","author":"M Mauer","year":"2009","unstructured":"Mauer M, Zinman B, Gardiner R, Suissa S, Sinaiko A, Strand T, et al. Renal and retinal effects of enalapril and losartan in type 1 diabetes. N Engl J Med. 2009;361(1):40\u201351.","journal-title":"N Engl J Med"},{"issue":"10","key":"2763_CR37","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.2337\/diacare.20.10.1576","volume":"20","author":"J Ahmad","year":"1997","unstructured":"Ahmad J, Siddiqui MA, Ahmad H. Effective postponement of diabetic nephropathy with enalapril in normotensive type 2 diabetic patients with microalbuminuria. Diabetes Care. 1997;20(10):1576\u201381.","journal-title":"Diabetes Care"},{"issue":"12 Part 1","key":"2763_CR38","doi-asserted-by":"publisher","first-page":"982","DOI":"10.7326\/0003-4819-128-12_Part_1-199806150-00004","volume":"128","author":"M Ravid","year":"1998","unstructured":"Ravid M, Brosh D, Levi Z, Bar-Dayan Y, Ravid D, Rachmani R. Use of enalapril to attenuate decline in renal function in normotensive, normoalbuminuric patients with type 2 diabetes mellitus: a randomized, controlled trial. Ann Intern Med. 1998;128(12 Part 1):982\u20138.","journal-title":"Ann Intern Med"},{"issue":"4","key":"2763_CR39","doi-asserted-by":"publisher","first-page":"843","DOI":"10.2337\/diabetes.50.4.843","volume":"50","author":"European Study for the Prevention of Renal Disease in Type 1 Diabetes ESPRIT Study Group","year":"2001","unstructured":"European Study for the Prevention of Renal Disease in Type 1 Diabetes ESPRIT Study Group. Effect of 3 Years of Antihypertensive Therapy on Renal Structure in Type 1 Diabetic Patients With Albuminuria: The European Study for the Prevention of Renal Disease in Type 1 Diabetes (ESPRIT). Diabetes. 2001;50(4):843\u201350.","journal-title":"Diabetes"},{"issue":"5","key":"2763_CR40","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1038\/ki.1996.480","volume":"50","author":"GL Bakris","year":"1996","unstructured":"Bakris GL, Copley JB, Vicknair N, Sadler R, Leurgans S. Calcium channel blockers versus other antihypertensive therapies on progression of NIDDM associated nephropathy. Kidney Int. 1996;50(5):1641\u201350.","journal-title":"Kidney Int"},{"issue":"12","key":"2763_CR41","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.2337\/diacare.23.12.1725","volume":"23","author":"L Tarnow","year":"2000","unstructured":"Tarnow L, Rossing P, Jensen C, Hansen BV, Parving H-H. Long-term renoprotective effect of nisoldipine and lisinopril in type 1 diabetic patients with diabetic nephropathy. Diabetes Care. 2000;23(12):1725\u201330.","journal-title":"Diabetes Care"},{"issue":"3","key":"2763_CR42","first-page":"185","volume":"10","author":"C-D Agardh","year":"1996","unstructured":"Agardh C-D, Garcia-Puig J, Charbonnel B, Angelkort B, Barnett A. Greater reduction of urinary albumin excretion in hypertensive type II diabetic patients with incipient nephropathy by lisinopril than by nifedipine. J Hum Hypertens. 1996;10(3):185.","journal-title":"J Hum Hypertens"},{"issue":"1","key":"2763_CR43","doi-asserted-by":"publisher","first-page":"42","DOI":"10.2165\/00044011-199700131-00009","volume":"13","author":"R Fogari","year":"1997","unstructured":"Fogari R, Zoppi A, Malamani G, Lusardi P, Destro M, Corradi L. Effects of amlodipine vs enalapril on microalbuminuria in hypertensive patients with type II diabetes. Clin Drug Investig. 1997;13(1):42\u20139.","journal-title":"Clin Drug Investig"},{"issue":"8","key":"2763_CR44","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1097\/01.hjh.0000133733.32125.09","volume":"22","author":"M Marre","year":"2004","unstructured":"Marre M, Puig JG, Kokot F, Fernandez M, Jermendy G, Opie L, et al. Equivalence of indapamide SR and enalapril on microalbuminuria reduction in hypertensive patients with type 2 diabetes: The NESTOR* study. J Hypertens. 2004;22(8):1613\u201322.","journal-title":"J Hypertens"},{"issue":"7","key":"2763_CR45","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1007\/s00228-005-0961-2","volume":"61","author":"R Fogari","year":"2005","unstructured":"Fogari R, Mugellini A, Zoppi A, Lazzari P, Destro M, Rinaldi A, et al. Effect of successful hypertension control by manidipine or lisinopril on albuminuria and left ventricular mass in diabetic hypertensive patients with microalbuminuria. Eur J Clin Pharmacol. 2005;61(7):483\u201390.","journal-title":"Eur J Clin Pharmacol"},{"key":"2763_CR46","first-page":"6","volume":"210","author":"Melbourne Diabetic Nephropathy Study Group","year":"1991","unstructured":"Melbourne Diabetic Nephropathy Study Group. Comparison between perindopril and nifedipine in hypertensive and normotensive diabetic patients with microalbuminuria. BMJ. 1991;210:6.","journal-title":"BMJ"},{"issue":"6860","key":"2763_CR47","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1136\/bmj.305.6860.981","volume":"305","author":"J Chan","year":"1992","unstructured":"Chan J, Cockram C, Nicholls M, Cheung C, Swaminathan R. Comparison of enalapril and nifedipine in treating non-insulin dependent diabetes associated with hypertension: one year analysis. BMJ. 1992;305(6860):981\u20135.","journal-title":"BMJ"},{"issue":"6 pt 1","key":"2763_CR48","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1161\/01.HYP.21.6.786","volume":"21","author":"Y Lacourciere","year":"1993","unstructured":"Lacourciere Y, Nadeau A, Poirier L, Tancrede G. Captopril or conventional therapy in hypertensive type II diabetics. Three-year analysis. Hypertension. 1993;21(6 pt 1):786\u201394.","journal-title":"Hypertension"},{"issue":"12","key":"2763_CR49","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1007\/s001250050623","volume":"39","author":"C Schnack","year":"1996","unstructured":"Schnack C, Hoffmann W, Hopmeier P, Schernthaner G. Renal and metabolic effects of 1-year treatment with ramipril or atenolol in NIDDM patients with microalbuminuria. Diabetologia. 1996;39(12):1611\u20136.","journal-title":"Diabetologia"},{"issue":"1","key":"2763_CR50","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/sj.jhh.1000732","volume":"13","author":"R Fogari","year":"1999","unstructured":"Fogari R, Zoppi A, Corradi L, Mugellini A, Lazzari P, Preti P, et al. Long-term effects of ramipril and nitrendipine on albuminuria in hypertensive patients with type II diabetes and impaired renal function. J Hum Hypertens. 1999;13(1):47\u201353.","journal-title":"J Hum Hypertens"},{"issue":"23","key":"2763_CR51","first-page":"54","volume":"2000","author":"R Schrier","year":"2000","unstructured":"Schrier R. Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. Diab Care. 2000;2000(23):54\u201364.","journal-title":"Diab Care"},{"issue":"12","key":"2763_CR52","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1056\/NEJMoa011303","volume":"345","author":"EJ Lewis","year":"2001","unstructured":"Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, et al. The Collaborative Study Group. Renoprotective Effect of the Angiotensin-Receptor Antagonist Irbesartan in Patients with Nephropathy Due to Type 2 Diabetes. N Engl J Med. 2001;345(12):851\u201360.","journal-title":"N Engl J Med"},{"key":"2763_CR53","doi-asserted-by":"publisher","first-page":"S150","DOI":"10.1038\/ki.1994.18","volume":"45","author":"HE Lebovitz","year":"1994","unstructured":"Lebovitz HE, Wiegmann TB, Cnaan A, Shahinfar S, Sica DA, Broadstone V, et al. Renal protective effects of enalapril in hypertensive NIDDM: role of baseline albuminuria. Kidney Int Suppl. 1994;45:S150-5.","journal-title":"Kidney Int Suppl"},{"issue":"3","key":"2763_CR54","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/S0168-8227(01)00288-1","volume":"54","author":"S Baba","year":"2001","unstructured":"Baba S, Group J-MS. Nifedipine and enalapril equally reduce the progression of nephropathy in hypertensive type 2 diabetics. Diabetes Res Clin Pract. 2001;54(3):191\u2013201.","journal-title":"Diabetes Res Clin Pract"},{"issue":"1","key":"2763_CR55","doi-asserted-by":"publisher","first-page":"11","DOI":"10.7326\/0003-4819-151-1-200907070-00120","volume":"151","author":"R Bilous","year":"2009","unstructured":"Bilous R, Chaturvedi N, Sj\u00f8lie AK, Fuller J, Klein R, Orchard T, et al. Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes: three randomized trials. Ann Intern Med. 2009;151(1):11\u201320.","journal-title":"Ann Intern Med"},{"issue":"4","key":"2763_CR56","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1001\/jama.1994.03510280037029","volume":"271","author":"G Viberti","year":"1994","unstructured":"Viberti G, Mogensen CE, Groop LC, Pauls JF, Boner G, Van Dyk D, et al. Effect of captopril on progression to clinical proteinuria in patients with insulin-dependent diabetes mellitus and microalbuminuria. JAMA. 1994;271(4):275\u20139.","journal-title":"JAMA"},{"issue":"2","key":"2763_CR57","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/S0168-8227(03)00016-0","volume":"60","author":"J Ahmad","year":"2003","unstructured":"Ahmad J, Shafique S, Abidi SA, Parwez I. Effect of 5-year enalapril therapy on progression of microalbuminuria and glomerular structural changes in type 1 diabetic subjects. Diabetes Res Clin Pract. 2003;60(2):131\u20138.","journal-title":"Diabetes Res Clin Pract"},{"issue":"7","key":"2763_CR58","first-page":"41","volume":"9","author":"M Dalla Vestra","year":"2004","unstructured":"Dalla Vestra M, Pozza G, Mosca A, Grazioli V, Lapolla A, Fioretto P, et al. Effect of lercanidipine compared with ramipril on albumin excretion rate in hypertensive Type 2 diabetic patients with microalbuminuria: DIAL Study (Diabete, Ipertensione, Albuminuria, Lercanidipina). Cardiovascular Therapy and Prevention. 2004;9(7):41\u20138.","journal-title":"Cardiovascular Therapy and Prevention"},{"issue":"3","key":"2763_CR59","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1046\/j.1523-1755.2002.00213.x","volume":"61","author":"RW Schrier","year":"2002","unstructured":"Schrier RW, Estacio RO, Esler A, Mehler P. Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. Kidney Int. 2002;61(3):1086\u201397.","journal-title":"Kidney Int"},{"key":"2763_CR60","unstructured":"Deeks JJ, Higgins JP, Altman DG. Cochrane Handbook for Systematic Reviews of Interventions Version 6.2.0 [updated 2021]. In: Higgins J, Thomas J, editors.: The Cochrane Collaboration; 2021.\u00a0www.training.cochrane.org\/handbook."},{"issue":"4S","key":"2763_CR61","first-page":"S1","volume":"98","author":"KDIGO Diabetes Work Group","year":"2020","unstructured":"KDIGO Diabetes Work Group. KDIGO 2020 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney International Supplements. 2020;98(4S):S1\u2013115.","journal-title":"Kidney International Supplements"},{"key":"2763_CR62","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1056\/NEJMoa011161","volume":"345","author":"BM Brenner","year":"2001","unstructured":"Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving H-H, et al. Effects of Losartan on Renal and Cardiovascular Outcomes in Patients with Type 2 Diabetes and Nephropathy. N Engl J Med. 2001;345:861\u20139.","journal-title":"N Engl J Med"},{"issue":"1","key":"2763_CR63","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.amjmed.2020.05.039","volume":"134","author":"EH Cativo","year":"2020","unstructured":"Cativo EH, Lopez PD, Cativo DP, Atlas SA, Rosendorff C. The Effect of Calcium Channel Blockers on Moderate or Severe Albuminuria in Diabetic, Hypertensive Patients. Am J Med. 2020;134(1):104-13E3.","journal-title":"Am J Med"},{"issue":"23","key":"2763_CR64","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","volume":"383","author":"GL Bakris","year":"2020","unstructured":"Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Rossing P, et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med. 2020;383(23):2219\u201329.","journal-title":"N Engl J Med"},{"issue":"11","key":"2763_CR65","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/S2213-8587(19)30256-6","volume":"7","author":"BL Neuen","year":"2019","unstructured":"Neuen BL, Young T, Heerspink HJ, Neal B, Perkovic V, Billot L, et al. SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2019;7(11):845\u201354.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"6","key":"2763_CR66","doi-asserted-by":"publisher","first-page":"3487","DOI":"10.1002\/ehf2.13002","volume":"7","author":"F Spannella","year":"2020","unstructured":"Spannella F, Giulietti F, Filipponi A, Sarzani R. Effect of sacubitril\/valsartan on renal function: a systematic review and meta-analysis of randomized controlled trials. ESC heart failure. 2020;7(6):3487\u201396.","journal-title":"ESC heart failure"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-022-02763-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-022-02763-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-022-02763-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,28]],"date-time":"2022-04-28T13:29:01Z","timestamp":1651152541000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-022-02763-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,28]]},"references-count":66,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["2763"],"URL":"https:\/\/doi.org\/10.1186\/s12882-022-02763-1","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,28]]},"assertion":[{"value":"13 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"JPL reported honoraria from Amgen Canada, AstraZeneca Canada, and Otsuka Canada for work not related to this study. SH reported honoraria from AstraZeneca Canada, and research support from GSK and Merck unrelated to this study. The remaining authors have declared no conflict of interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"161"}}